Key Predictors of IgG Seropositivity in Individuals Exposed to SARS-CoV-2 Prior to Vaccine Rollout
Archives of Advances in Biosciences,
Vol. 16 No. 1 (2025),
2 March 2025
,
Page 1-9
https://doi.org/10.22037/aab.v15i1.46911
Abstract
Introduction: The COVID-19 pandemic has highlighted the need to understand factors influencing the immune response to SARS-CoV-2. Immunoglobulin G (IgG) antibodies serve as indicators of prior exposure and potential immunity. This study aims to identify demographic, clinical, and exposure-related predictors of IgG positivity in individuals exposed to SARS-CoV-2 before the initiation of vaccination programs.
Materials and Methods: A cross-sectional study was conducted among 944 participants recruited from healthcare facilities. Eligible participants were aged 18 years or older, presented with COVID-19 symptoms or known exposure to confirmed SARS-CoV-2 cases, and had not received a COVID-19 vaccine. Data were collected via structured questionnaires, including demographics, clinical symptoms, and exposure history, and analyzed using logistic regression. IgG antibodies were detected using the SARS-CoV-2 IgG ELISA method.
Results: IgG antibodies were detected in 75.0% of participants. Younger age (B = -0.026, p < 0.001), divorced marital status (B = 0.973, p = 0.021, Exp(B) = 2.65), recent international travel (B = 0.953, p = 0.047, Exp(B) = 2.594), and symptoms such as runny nose (B = 2.561, p = 0.012, Exp(B) = 12.96), nausea (B = 1.614, p = 0.048, Exp(B) = 5.025), and lack of appetite (B = 1.366, p = 0.049, Exp(B) = 3.918) were significant predictors of IgG positivity. Each additional year of age was associated with a 2.6% reduction in the likelihood of IgG positivity. The model achieved 75.4% classification accuracy with an AUC of 0.640, indicating moderate predictive performance.
Conclusion: This study demonstrates the importance of demographic, clinical, and exposure-related factors in predicting IgG positivity. The findings enhance understanding of immune responses to SARS-CoV-2 and provide insights that can guide public health strategies in mitigating the pandemic's impact.
- COVID 19
- SARS CoV 2
- IgG antibodies
- Immune response
- Logistic regression
How to Cite
References
[1] Wu J, Liang B, Chen C, Wang H, Fang Y, Shen S, et al. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. Nat Commun. 2021;12(1):1813. [DOI: 10.1038/s41467-021-22034-1] [PMID] [PMCID]
[2] Lytton SD, Yeasmin M, Ghosh AK, Bulbul MRH, Molla MMA, Herr M, et al. Detection of anti-nucleocapsid antibody in COVID-19 patients in Bangladesh is not correlated with previous dengue infection. Pathogens. 2021;10(6):637. [DOI: 10.3390/pathogens10060637] [PMID] [PMCID]
[3] Sze S, Pan D, Nevill CR, Gray LJ, Martin CA, Nazareth J, et al. Ethnicity and clinical outcomes in COVID-19: a systematic review and meta-analysis. EClinicalMedicine. 2020;29-30:100630. [DOI: 10.1016/j.eclinm.2020.100630] [PMID] [PMCID]
[4] Holmes L Jr, Enwere M, Williams J, Ogundele B, Chavan P, Piccoli T, et al. Black-White risk differentials in COVID-19 (SARS-COV2) transmission, mortality and case fatality in the United States: translational epidemiologic perspective and challenges. Int J Environ Res Public Health. 2020;17(12):4322. [DOI: 10.3390/ijerph17124322] [PMID] [PMCID]
[5] Sun B, Feng Y, Mo X, Zheng P, Wang Q, Li P, et al. Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients. Emerg Microbes Infect. 2020;9(1):940-948. [DOI: 10.1080/22221751.2020.1762515] [PMID] [PMCID]
[6] To KKW, Tsang OTY, Leung WS, Tam AR, Wu TC, Lung DC, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020;20(5):565-574. [DOI: 10.1016/S1473-3099(20)30196-1] [PMID] [PMCID]
[7] Galanis P, Vraka I, Fragkou D, Bilali A, Kaitelidou D. Seroprevalence of SARS-CoV-2 antibodies and associated factors in healthcare workers: a systematic review and meta-analysis. J Hosp Infect. 2021;108:120-134. [DOI: 10.1016/j.jhin.2020.11.008] [PMID] [PMCID]
[8] Lumley SF, Wei J, O'Donnell D, Stoesser NE, Matthews PC, Howarth A, et al. The duration, dynamics, and determinants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody responses in individual healthcare workers. Clin Infect Dis. 2021;73(3):e699-e709. [DOI: 10.1093/cid/ciab004] [PMID] [PMCID]
[9] Cordova E, Bacelar B, Nieto F, Garibaldi F, Aguirre V, Machuca M, et al. SARS-CoV-2 IgG response in symptomatic and asymptomatic COVID-19-infected healthcare workers. Occup Med (Lond). 2021;71(4-5):215-218. [DOI: 10.1093/occmed/kqab061] [PMID] [PMICD]
[10] Cervia C, Nilsson J, Zurbuchen Y, Valaperti A, Schreiner J, Wolfensberger A, et al. Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19. J Allergy Clin Immunol. 2021;147(2):545-557.e9. [DOI: 10.1016/j.jaci.2020.10.040] [PMID] [PMCID]
[11] Butterfield TR, Bruce-Mowatt A, Phillips YZR, Brown N, Francis K, Brown J, et al. Assessment of commercial SARS-CoV-2 antibody assays, Jamaica. Int J Infect Dis. 2021;105:333-336. [DOI: 10.1016/j.ijid.2021.02.059] [PMID] [PMCID]
[12] Kaku N, Nishimura F, Shigeishi Y, Tachiki R, Sakai H, Sasaki D, et al. Performance of anti-SARS-CoV-2 antibody testing in asymptomatic or mild COVID-19 patients: a retrospective study in outbreak on a cruise ship. PLoS One. 2021;16(9):e0257452. [DOI: 10.1371/journal.pone.0257452] [PMID] [PMCID]
[13] Torres Martínez P, Diaque García P, Rubio Salas M, Rodríguez Sánchez R, Avendaño-Ortíz J, Guerrero-Monjo S, et al. SARS-CoV-2 IgG seropositivity in a cohort of 449 non-hospitalized individuals during Spanish COVID-19 lockdown. Sci Rep. 2021;11(1):21612. [DOI: 10.1038/s41598-021-00990-4] [PMID] [PMCID]
[14] Hu F, Shang X, Chen M, Zhang C. Joint detection of serum IgM/IgG antibody is an important key to clinical diagnosis of SARS-CoV-2 infection. Can J Infect Dis Med Microbiol. 2020;2020:1020843. [DOI: 10.1155/2020/1020843] [PMID] [PMCID]
[15] Mahallawi WH, Al-Zalabani AH. The seroprevalence of SARS-CoV-2 IgG antibodies among asymptomatic blood donors in Saudi Arabia. Saudi J Biol Sci. 2021;28(3):1697-1701. [DOI: 10.1016/j.sjbs.2020.12.009] [PMID] [PMCID]
[16] Cosgun Y, Altas AB, Akkan Kuzucu E, Guner R, Erdinc S, Eser F, et al. Role of rapid antibody and ELISA tests in the evaluation of serological response in patients with SARS-CoV-2 PCR positivity. Folia Microbiol (Praha). 2021;66(4):579-586. [DOI: 10.1007/s12223-021-00861-5] [PMID] [PMCID]
[17] Özdemir Yalçınsoy K, Güngör A, Karakaya D, Özdal L, Kılıç M, Özdamar Erol Y, et al. Tubulointerstitial nephritis and uveitis syndrome during the COVID-19 pandemic: a case series. Turk J Ophthalmol. 2024;54(1):5-10. [DOI: 10.4274/tjo.galenos.2023.24280] [PMID] [PMCID]
- Abstract Viewed: 380 times
- PDF Downloaded: 13 times